Regeneron Pharmaceuticals, Inc.

Key catalysts

• Dupixent expansion

  New indications, age groups and geographies can extend a broad type-2 inflammation franchise.

• EYLEA HD conversion

  Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry.

• Internal pipeline

  Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

Principal risks

• Retinal competition

  Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share.

• Partner economics

  Profit-sharing and dependence on collaborators shape the cash economics of major products.

• Pipeline attrition

  Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

Regeneron's first-quarter 2026 update highlighted Dupixent's continued global expansion, execution across the EYLEA HD retinal franchise and investment in oncology, immunology and genetic-medicine programs.

Valuation interpretation

• Dupixent durability and successful EYLEA HD conversion anchor value while retinal competition remains a material offset.
• The internal pipeline deserves option value, but commercialization and partner economics require asset-by-asset risk adjustment.